We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-0.06%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$70.9M
AUM Growth
+$13.4M
Cap. Flow
+$13.8M
Cap. Flow %
19.5%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LVO icon
LiveOne
LVO
+$14.2M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$341K

Sector Composition

Rank Sector Weight
1 Healthcare 80.69%
2 Communication Services 19.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
1
Tvardi Therapeutics
TVRD
$23.5M
$44.2M 62.3%
99,113
– –
LVO icon
2
LiveOne
LVO
$66M
$13.7M 19.31%
+360,294
New +$14.2M
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$12.6M 17.71%
31,858
-863
-3% -$341K
SENS icon
4
Senseonics Holdings Inc
SENS
$254M
$479K 0.68%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Rho Capital Partners held 4 positions worth $70.9M, up 23% from $57.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners deployed $13.8M of net new capital in Q1 2018, opening 1 new position. Its largest new stake was LiveOne: 360,294 shares worth $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 100% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $341K trimmed.

  • Rho Capital Partners's largest Q1 2018 buy was LiveOne: 360,294 shares worth $13.7M.
  • Rho Capital Partners's biggest Q1 2018 reduction was Mersana Therapeutics, cutting an estimated $341K.
  • Rho Capital Partners's ten largest holdings make up 100% of its $70.9M portfolio in Q1 2018.
  • Rho Capital Partners opened 1 new position and closed 0 in Q1 2018.
  • Rho Capital Partners's portfolio value rose 23% quarter-over-quarter to $70.9M.

Based on Rho Capital Partners's 13F filing for Q1 2018, filed 9 May 2018.